secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001493152-25-021195
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology presents THIO-104 and THIO-101 posters at SITC 2025 for NSCLC trials
--------------------------------------------------------------------------------

- THIO-104 Phase 3 study of ategano sine (THIO) sequenced with ICI vs SOC chemo in ICI-resistant advanced NSCLC presented Nov 7.
- THIO-101 Phase 2 study of THIO combined with ICI in advanced NSCLC resistant to prior ICI and chemo presented Nov 10.
- Posters are in-progress trial updates and contain forward-looking statements; detailed results not disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225021195/0001493152-25-021195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225021195/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer